Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BCTX | US
-0.30
-6.49%
Healthcare
Biotechnology
30/04/2024
16/04/2026
4.32
4.60
4.61
4.25
BriaCell Therapeutics Corp. an immuno-oncology-focused biotechnology company engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver Canada.
View LessNegative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
61.9%1 month
71.0%3 months
67.8%6 months
139.7%-
-
17.03
-
-
-1.38
-
-
-35.25M
155.04M
155.04M
-
-
-
-
-206.01
0.04
1.56
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.71
Range1M
0.94
Range3M
1.56
Rel. volume
1.17
Price X volume
861.17K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Adagene Inc. | ADAG | Biotechnology | 3.85 | 170.44M | 0.79% | n/a | 36.29% |
| Protalix BioTherapeutics Inc | PLX | Biotechnology | 2.3 | 169.15M | -3.36% | n/a | 91.50% |
| OBIO | OBIO | Biotechnology | 4.47 | 169.08M | -2.19% | n/a | 3.29% |
| Vaxart Inc | VXRT | Biotechnology | 0.728 | 165.58M | -0.21% | n/a | 28.91% |
| Candel Therapeutics Inc. Common Stock | CADL | Biotechnology | 5.16 | 165.56M | 0.19% | n/a | -186.13% |
| Connect Biopharma Holdings Limited American Depositary Shares | CNTB | Biotechnology | 2.99 | 165.21M | 2.05% | n/a | 0.29% |
| Achieve Life Sciences Inc | ACHV | Biotechnology | 4.81 | 165.18M | 35.49% | n/a | 41.73% |
| Immuneering Corporation Class A Common Stock | IMRX | Biotechnology | 5.57 | 165.17M | -3.13% | n/a | 6.50% |
| BLACK DIAMOND THERAPEUTICS INC. | BDTX | Biotechnology | 2.92 | 164.99M | 1.74% | n/a | 21.42% |
| Acumen Pharmaceuticals Inc. Common Stock | ABOS | Biotechnology | 2.69 | 161.61M | -1.10% | n/a | 11.57% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 9.74 | 156.39M | 0.72% | n/a | 286.96% |
| Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 34.99 | 100.48M | 0.63% | 5.16 | 19.82% |
| Virco Mfg. Corporation | VIRC | Building Products & Equipment | 6.12 | 99.69M | 0.49% | 9.09 | 39.79% |
| Saga Communications Inc | SGA | Broadcasting - Radio | 11.93 | 74.70M | 1.14% | 14.48 | 7.10% |
| ILAG | ILAG | Building Products & Equipment | 3.32 | 59.96M | 0.00% | n/a | 5.48% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 14 | 21.32M | 2.04% | n/a | 204.46% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.612 | 11.83M | -2.84% | n/a | 58.43% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.74 | 10.81M | 6.52% | 0.03 | 16.03% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.335 | 3.41M | -2.06% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2167 | 2.06M | -6.19% | n/a | 19.98% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.38 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 17.03 | 15.55 | Par |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 67.83 | - | Par |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 155.04M | - | Emerging |